Structural Characteristics and Research Progress in Applications of BTN1A1 Fc Chimeric Protein

I. Structural and Functional Characteristics of BTN1A1 Protein

BTN1A1 (Butyrophilin Subfamily 1 Member A1) belongs to the butyrophilin family and is an important type I transmembrane protein. Structurally, it contains an extracellular immunoglobulin variable-like (IgV) domain, an immunoglobulin constant-like (IgC) domain, a transmembrane domain, and an intracellular domain. The IgV domain contains specific binding sites that mediate protein-protein interactions, while the IgC domain contributes to protein stability and conformational integrity.

Functionally, BTN1A1 is predominantly highly expressed in mammary epithelial cells and serves as a key regulatory factor in milk lipid droplet secretion. Recent studies have revealed its involvement in T cell activation and immune tolerance regulation. Through interactions with specific receptors, BTN1A1 can influence the activation and function of γδ T cells. Additionally, this protein demonstrates significant regulatory roles in tumor microenvironments and autoimmune diseases, indicating its broad immunomodulatory functions.

II. Design Principles and Structural Advantages of Fc Fusion Proteins

Fc fusion protein technology involves the genetic engineering of target protein extracellular domains fused with immunoglobulin (typically IgG) Fc fragments. For BTN1A1 Fc fusion proteins, the design strategy primarily includes:

Structural Composition: The fusion protein consists of the complete extracellular domain of BTN1A1 fused with the Fc region of human IgG1. This design preserves BTN1A1's natural ligand-binding capacity while incorporating the properties of IgG Fc fragments.

Functional Properties: The inclusion of the Fc fragment significantly enhances protein stability and half-life. The human IgG1 Fc fragment mediates interactions with Fc receptors while minimizing immunogenicity, a critical feature for therapeutic applications. Additionally, the Fc fragment facilitates efficient protein purification via Protein A/G affinity chromatography.

Molecular Form: Through disulfide bonds, the BTN1A1 Fc fusion protein exists as a homodimer, a multivalent structure that enhances ligand-binding affinity and functional effects.

III. Preparation and Quality Control of BTN1A1 Fc Fusion Protein

BTN1A1 Fc fusion protein production typically employs mammalian expression systems to ensure proper post-translational modifications such as glycosylation.

Expression System Selection: Chinese hamster ovary (CHO) cells or human embryonic kidney (HEK293) cells are commonly used hosts. These systems enable efficient secretory expression of recombinant proteins and complex glycosylation modifications.

Purification Process: A multi-step chromatography strategy is employed. Protein A affinity chromatography serves as the capture step for effective target protein isolation, followed by ion-exchange chromatography and size-exclusion chromatography to remove impurities and aggregates, yielding high-purity monomeric protein.

Quality Control Metrics Include: Purity analysis via SDS-PAGE and HPLC (monomer purity >95%); glycosylation profiling by mass spectrometry; biological activity assessed by surface plasmon resonance (SPR) or ELISA for ligand-binding capacity; endotoxin levels meeting pharmaceutical standards.

IV. Applications of BTN1A1 Fc Fusion Protein in Biomedical Research

BTN1A1 Fc fusion protein has diverse applications in research.

Mechanistic Research Tool: As a soluble receptor, it studies BTN1A1-ligand interaction mechanisms. Blocking experiments can elucidate BTN1A1's roles in immune regulation and cell signaling.

Drug Screening Platform: In cell-based assays, it screens compounds modulating BTN1A1 pathways, providing a vital tool for drug development.

Immunomodulation Studies: Investigates its role in T cell activation and tolerance, offering experimental foundations for immune-related disease therapies.

Diagnostic Reagent Development: Serves as detection antigen or capture reagent for developing assays targeting BTN1A1 ligands or related antibodies.

V. Suppliers of BTN1A1 Fc Chimera Protein

Nanjing U-Protein Biotechnology independently developed the BTN1A1/Butyrophilin Fc Chimera Protein, Human, a high-purity, high-activity human recombinant fusion protein. Through genetic engineering, the BTN1A1 extracellular domain is fused with human immunoglobulin Fc fragment. This product maintains native conformation and full biological functionality, suitable for immune regulation studies, T cell function analysis, antibody screening, immunoprecipitation (IP), flow cytometry, and other applications, providing a reliable tool protein for immunology research and drug development.

Core Product Advantages:

Nanjing U-Protein Biotechnology specializes in high-quality recombinant proteins and reagents for immunology, cancer immunotherapy, and antibody drug development. For detailed specifications (BTN1A1 Fc Chimera Protein, Human, Cat#: UA011184), activity validation data, or application support, please contact us.